672 related articles for article (PubMed ID: 19640589)
1. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles.
Skerka C; Licht C; Mengel M; Uzonyi B; Strobel S; Zipfel PF; Józsi M
Mol Immunol; 2009 Sep; 46(14):2801-7. PubMed ID: 19640589
[TBL] [Abstract][Full Text] [Related]
2. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
Polito MG; Kirsztajn GM
J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies in haemolytic uraemic syndrome (HUS).
Skerka C; Józsi M; Zipfel PF; Dragon-Durey MA; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):227-32. PubMed ID: 19190803
[TBL] [Abstract][Full Text] [Related]
4. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
5. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
Licht C; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
[TBL] [Abstract][Full Text] [Related]
6. Pathological aspects of membranoproliferative glomerulonephritis (MPGN) and haemolytic uraemic syndrome (HUS) / thrombocytic thrombopenic purpura (TTP).
Benz K; Amann K
Thromb Haemost; 2009 Feb; 101(2):265-70. PubMed ID: 19190808
[TBL] [Abstract][Full Text] [Related]
7. Thrombotic microangiopathies: new insights and new challenges.
Zipfel PF; Heinen S; Skerka C
Curr Opin Nephrol Hypertens; 2010 Jul; 19(4):372-8. PubMed ID: 20539230
[TBL] [Abstract][Full Text] [Related]
8. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
[TBL] [Abstract][Full Text] [Related]
9. Plasma von Willebrand Factor Antigen (vWF:AG) and thrombomodulin (TM) levels in Adult Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM).
Zeigler ZR; Rosenfeld CS; Andrews DF; Nemunaitis J; Raymond JM; Shadduck RK; Kramer RE; Gryn JF; Rintels PB; Besa EC; George JN
Am J Hematol; 1996 Dec; 53(4):213-20. PubMed ID: 8948657
[TBL] [Abstract][Full Text] [Related]
10. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
11. [Clinical analysis on thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, with plasma level of cytokine].
Wada H; Saitoh M; Tamaki S; Masuya M; Morita K; Tabata M; Tanigawa M; Kageyama S; Tsuzi K; Ohta C
Rinsho Ketsueki; 1990 Sep; 31(9):1537-43. PubMed ID: 2246829
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology and treatment of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS).
Kakishita E
Int J Hematol; 2000 Jun; 71(4):320-7. PubMed ID: 10905050
[TBL] [Abstract][Full Text] [Related]
13. Three kidneys, two diseases, one antibody?
Lorcy N; Rioux-Leclercq N; Lombard ML; Le Pogamp P; Vigneau C
Nephrol Dial Transplant; 2011 Nov; 26(11):3811-3. PubMed ID: 21813829
[TBL] [Abstract][Full Text] [Related]
14. The autoimmune disease DEAP-hemolytic uremic syndrome.
Skerka C; Zipfel PF; Müller D; Micklisch S; Riedl M; Zimmerhackl LB; Hofer J
Semin Thromb Hemost; 2010 Sep; 36(6):625-32. PubMed ID: 20865639
[TBL] [Abstract][Full Text] [Related]
15. The role of von Willebrand factor in thrombotic microangiopathy.
Noone DG; Riedl M; Licht C
Pediatr Nephrol; 2018 Aug; 33(8):1297-1307. PubMed ID: 28748411
[TBL] [Abstract][Full Text] [Related]
16. [Thrombotic thrombocytopenic purpura in children -- pathophysiologic mechanisms and their clinical significance].
Korczowski B
Med Wieku Rozwoj; 2005; 9(4):753-61. PubMed ID: 16733283
[TBL] [Abstract][Full Text] [Related]
17. [Hemolytic uremic syndrome (HUS): pathophysiology--with reference to the differentiation between HUS and thrombotic thrombocytopenic purpura].
Naruse T
Nihon Rinsho; 1993 Jan; 51(1):187-92. PubMed ID: 8433517
[TBL] [Abstract][Full Text] [Related]
18. Extracorporeal plasma treatment in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: a review.
Bosch T; Wendler T
Ther Apher; 2001 Jun; 5(3):182-5. PubMed ID: 11467754
[TBL] [Abstract][Full Text] [Related]
19. Platelet activation in hemolytic uremic syndrome.
Karpman D; Manea M; Vaziri-Sani F; Ståhl AL; Kristoffersson AC
Semin Thromb Hemost; 2006 Mar; 32(2):128-45. PubMed ID: 16575688
[TBL] [Abstract][Full Text] [Related]
20. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.
Lee BH; Kwak SH; Shin JI; Lee SH; Choi HJ; Kang HG; Ha IS; Lee JS; Dragon-Durey MA; Choi Y; Cheong HI
Pediatr Res; 2009 Sep; 66(3):336-40. PubMed ID: 19531976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]